• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake - Product Image

Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake

  • Published: March 2013
  • Region: Global
  • 115 Pages
  • GBI Research

GBI Research, the leading business intelligence provider, has released its latest research “Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake”. There is currently only one marketed therapeutic cancer vaccine, Provenge, which is indicated for the treatment of castrate¬–resistant, asymptomatic metastatic prostate cancer which achieved global sales of approximately $215 million in 2011.

Over the forecast period, numerous vaccines are anticipated to be approved over a range of indications including the commonly diagnosed lung and colorectal cancer types. All of these vaccines have been shown to improve patient survival, some by a few months, others by years. The high anticipated price tag of these vaccines will be a barrier of market growth.

However, due to the fact that numerous vaccines are anticipated to be approved across a range of highly diagnosed indications, GBI Research believes the global market does have the potential to grow to a value of $7.8 billion by 2019.

Scope

- The report analyzes treatment usage patterns, variation in READ MORE >

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Cancer Epidemiology
2.2 Disease Initiation and Propagation
2.3 Symptoms
2.3.1 Symptoms of Lung Cancer
2.3.2 Symptoms of Prostate Cancer
2.3.3 Symptoms of Colorectal Cancer
2.3.4 Symptoms of Breast Cancer
2.3.5 Symptoms of Melanoma
2.3.6 Symptoms of Stomach Cancer
2.4 Current Treatment and Management
2.4.1 Active Surveillance or the ‘Wait-and See’ Approach
2.4.2 Surgery
2.4.3 Radiation Therapy
2.4.4 Chemotherapy
2.4.5 Targeted Therapy
2.4.6 Hormone Therapy
2.4.7 Immunotherapy
2.5 Virally Induced Cancers and Prophylactic Vaccines
2.6 Cancer, the Immune system and Therapeutic Vaccines
2.6.1 Mechanisms of Immune System Evasion
2.6.2 Mechanisms of Immune System Disabling
2.7 Why Develop Therapeutic Cancer Vaccines?
2.8 Types of Therapeutic Cancer Vaccine
2.8.1 Anti-Idiotype Vaccines
2.8.2 Whole-Cell-Derived Vaccines
2.8.3 Cellular Immunotherapy
2.8.4 Antigen-Based Vaccines
2.8.5 DNA-Based Vaccines
2.8.6 Vector-Based (Microorganism-Facilitated) Vaccines
2.8.7 Oncolytic Virus Vaccines
2.8.8 Adjuvants

3 Marketed Products
3.1 Provenge – an Autologous Cellular Immunotherapy Vaccine for the Treatment of Hormone-Refractory Prostate Cancer
3.1.1 Overview
3.1.2 Mechanism of Action and Molecular Target
3.1.3 Formulation and Dosing
3.1.4 Provenge within the Clinical Landscape for Prostate Cancer
3.1.5 Company Profile and Patent Expiry
3.2 Recent Sales and Commercialization of Provenge
3.3 Current and Future Market Competitors for Provenge

4 Product Pipeline
4.1 Pipeline Overview
4.1.1 Developmental Pipeline of all Major Indications
4.1.2 Clinical Trials
4.1.3 Clinical Trial Failure
4.1.4 Key Companies Developing Cancer Vaccines
4.1.5 Promising Drugs in the Developmental Pipeline

5 Forecasting
5.1 Therapeutic Cancer Vaccines Market to 2019 – Global
5.1.1 Treatment Usage Patterns
5.1.2 Annual Cost of Treatment
5.2 Colorectal Cancer
5.2.1 Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Glioblastoma Multiforme
5.3.1 Emerging Cancer Vaccines and their Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Lymphoma
5.4.1 Emerging Cancer Vaccines for Lymphoma and their Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Revenues
5.5 Melanoma
5.5.1 Emerging Cancer Vaccines and Anticipated Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Non-Small-Cell Lung Cancer
5.6.1 Emerging Vaccines and Treatment Usage Patterns
5.6.2 Annual Cost of Therapy
5.6.3 Market Size
5.7 Pancreatic Cancer
5.7.1 Emerging Cancer Vaccines and their Market Impact
5.7.2 Annual Cost of Therapy
5.7.3 Market Revenues
5.8 Prostate Cancer
5.8.1 Treatment Usage Patterns and the Impact of Emerging Vaccines
5.8.2 Annual Cost of Treatment
5.8.3 Market Revenues
5.9 Drivers and Barriers for Therapeutic Cancer Vaccines Market
5.9.1 Drivers
5.9.2 Barriers

6 Appendix
6.1 Provenge Clinical Trial Titles (Table 3)
6.2 Predicated Annual Cost of Therapy
6.2.1 Colon Cancer
6.2.2 Glioblastoma Multiforme
6.2.3 Lymphoma
6.2.4 Melanoma
6.2.5 Non-Small-Cell Lung Cancer
6.2.6 Pancreatic Cancer
6.2.7 Prostate Cancer
6.3 Predicted Market Forecasts
6.3.1 Colon Cancer
6.3.2 Glioblastoma Multiforme
6.3.3 Lymphoma
6.3.4 Melanoma
6.3.5 Non-Small-Cell Lung Cancer
6.3.6 Pancreatic Cancer
6.3.7 Prostate
6.4 All Pipeline Drugs by Phase
6.4.1 Discovery
6.4.2 Preclinical
6.4.3 IND-Filed and Phase 0
6.4.4 Phase I
6.4.5 Phase II
6.4.6 Phase III
6.5 Market Definitions
6.6 Abbreviations
6.7 Sources
6.8 Research Methodology
6.8.1 Coverage
6.8.2 Secondary Research
6.8.3 Primary Research
6.8.4 Therapeutic Landscape
6.8.5 Epidemiology-Based Forecasting
6.8.6 Analogous Forecasting Methodology
6.8.7 Diseased Population
6.8.8 Prescription Population
6.9 Market Size by Geography
6.9.1 Forecasting Model for Therapeutic Areas
6.10 Geographical Landscape
6.11 Pipeline Analysis
6.12 Expert Panel Validation
6.13 Contact Us
6.14 Disclaimer

1.1 List of Tables

Table 1: Therapeutic Cancer Vaccines Market, Infectious Agents and Associated Cancer(s), 2011
Table 2: Dendreon Corporation, Global, Provenge, Revenue ($m), 2010–2011
Table 3: Therapeutic Cancer Vaccines Market, Provenge, Clinical Trials upto 2012
Table 4: Therapeutic Cancer Vaccines Market, Safety, Efficacy and Annual Cost of Therapy of Provenge, DCVax-Prostate and Prostvac, 2013-2019
Table 5: Therapeutic Cancer Vaccines Market, Global, Common Molecular Targets, 2013
Table 6: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, 1998–2012
Table 7: Therapeutic Cancer Vaccines Market, Global, Key Companies, 2013
Table 8: Therapeutic Cancer Vaccines Market, Global, Allovectin, Phase II Clinical Trial Results, up to 2012
Table 9: Therapeutic Cancer Vaccines Market, Global, Lucanix, Phase II Clinical Trial Results, 2006
Table 10: Therapeutic Cancer Vaccines Market, Global, Safety and Efficacy of Common Adjuvant Treatment Regimes for Glioblastoma Multiforme
Table 11: Therapeutic Cancer Vaccines Market, Global, Cost, Safety and Efficacy of Potential Adjuvant Chemotherapy Regimens for Stage II Colon Cancer
Table 12: Therapeutic Cancer Vaccines Market, Global, Safety and Efficacy of Adjuvant Chemotherapy Regimens for Glioblastoma Multiforme
Table 13: Therapeutic Cancer Vaccines Market, Global, Common Metastatic Melanoma Treatments and Vaccines Expected to be Approved, Safety and Efficacy,
Table 14: Colon Cancer, Global, Predicted Annual Cost of Therapy ($’000), 2015–2019
Table 15: Glioblastoma Multiforme, Global, Predicted Annual Cost of Therapy ($’000), 2015-2019
Table 16: Lymphoma, Global, Predicted Annual Cost of Therapy ($’000), 2013-2019
Table 17: Melanoma, Global, Predicted Annual Cost of Therapy ($’000), 2015-2019
Table 18: Non-Small-Cell Lung Cancer, Global, Predicted Annual Cost of Therapy ($’000), 2014-2018
Table 19: Pancreatic Cancer, Global, Predicted Annual Cost of Therapy ($’000), 2015-2019
Table 20: Prostate Cancer, Global, Predicted Annual Cost of Therapy ($’000), 2013-2019
Table 21: Colon Cancer, Global, Predicted Market Revenues ($m), 2015-2019
Table 22: Glioblastoma Multiforme, Global, Predicted Market Revenues ($m), 2015-2019
Table 23: Lymphoma, Global, Predicted Market Revenues ($m), 2013-2019
Table 24: Melanoma, Global, Predicted Market Revenues ($m), 2015-2019
Table 25: Non-Small-Cell Lung Cancer, Global, Predicted Market Revenues ($m), 2014-2019
Table 26: Pancreatic Cancer, Global, Predicted Market Revenues ($m), 2015-2019
Table 27: Prostate Cancer, Global, Predicted Market Revenues ($m), 2013-2019
Table 28: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Discovery Phase
Table 29: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Preclinical Phase
Table 30: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase 0 or IND-Filed
Table 31: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase I
Table 32: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase II
Table 33: Therapeutic Cancer Vaccines Market, Global, Developmental Pipeline, Phase III

1.2 List of Figures

Figure 1: Therapeutic Cancer Vaccines Market, Global, Common Cancers and Incidence Rates, 2008
Figure 2: Therapeutic Cancer Vaccines Market, Global, Pipeline Overview (%), 2013
Figure 3: Therapeutic Cancer Vaccines Market, Global, Pipeline by Indication, Incidence by Indication (million), 2013
Figure 4: Therapeutic Cancer Vaccines Market, Global, Lung Cancer, Pipeline Overview, 2013
Figure 5: Therapeutic Cancer Vaccines Market, Globa, Breast Cancer, Pipeline Overview, 2013
Figure 6: Therapeutic Cancer Vaccines Market, Global, Colorectal Cancer, Pipeline Overview, 2013
Figure 7: Therapeutic Cancer Vaccines Market, Global, Stomach Cancer, Pipeline Overview, 2013
Figure 8: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Pipeline Overview, 2013
Figure 9: Therapeutic Cancer Vaccines Market, Global, Melanoma, Pipeline Overview, 2012
Figure 10: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Duration (months), 1998–2012
Figure 11: Therapeutic Cancer Vaccines Market, Global, Cumulative Clinical Trial Duration (months), 1998–2012
Figure 12: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Size by Phase and Vaccine Type, 1998–2012
Figure 13: Therapeutic Cancer Vaccines Market, Global, Primary and Secondary Endpoints, Pipeline, 1998–2012
Figure 14: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Failure, Pass and Inferred Pass Rates, 2006–2012
Figure 15: Therapeutic Cancer Vaccines Market, Global, Clinical Trial Failure, 1998–2012
Figure 16: Therapeutic Cancer Vaccines Market, Global, Revenue Forecast ($bn), 2013–2019
Figure 17: Therapeutic Cancer Vaccines Market, Global, Colon Cancer, Target Market (‘000) and Annual Cost of Therapy ($’000) Forecast, 2015–2019
Figure 18: Therapeutic Cancer Vaccines Market, Global, Colon Cancer, Revenue Forecast ($m), 2015–2019
Figure 19: Therapeutic Cancer Vaccines Market, Global, Glioblastoma Multiforme, Target Market (‘000) and Annual Cost of Therapy ($’000) Forecast, 2015–2019
Figure 20: Therapeutic Cancer Vaccines Market, Global, Glioblastoma Multiforme, Revenue Forecast ($m), 2015–2019
Figure 21: Therapeutic Cancer Vaccines Market, Global, Lymphoma, Annual Cost of Therapy ($’000) and Target Market (‘000), 2013–2019
Figure 22: Therapeutic Cancer Vaccines Market, Global, Lymphoma, Revenue Forecast ($m), 2013–2019
Figure 23: Therapeutic Cancer Vaccines Market, Global, Melanoma, Annual Cost of Therapy ($’000) and Target Market (‘000), 2015–2019
Figure 24: Therapeutic Cancer Vaccines Market, Global, Melanoma, Revenue Forecast ($m), 2015–2019
Figure 25: Therapeutic Cancer Vaccines Market, Global, Non-Small-Cell Lung Cancer, Annual Cost of Therapy ($’000) and Target Market (‘000), 2014–2019
Figure 26: Therapeutic Cancer Vaccines Market, Global, Non-Small-Cell Lung Cancer, Annual Cost of Therapy ($’000) and Target Market (‘000), 2014–2019
Figure 27: Therapeutic Cancer Vaccines Market, Global, Pancreatic Cancer, Annual Cost of Treatment ($’000) and Target Market (‘000), 2015–2019
Figure 28: Therapeutic Cancer Vaccines Market, Global, Pancreatic Cancer, Revenue Forecast ($m), 2015–2019
Figure 29: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Annual Cost of Treatment ($’000) and Target Market (‘000), 2013–2019
Figure 30: Therapeutic Cancer Vaccines Market, Global, Prostate Cancer, Revenue Forecast ($m), 2013–2019
Figure 31: GBI Research Market Forecasting Model

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos